Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

ACT001 per il trattamento di gliomi pontini intrinseci diffusi e gliomi di alta qualità alterati da H3K27

22 ottobre 2026 aggiornato da: Nationwide Children's Hospital

Uno studio di fase II di ACT001 in bambini e adolescenti con gliomi pontini intrinseci diffusi e gliomi di alto livello di H3K27

This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Patients will be enrolled on either Cohort A for newly diagnosed DIPG or on Cohort B [ENROLLMENT PAUSED] for those with progressive / refractory DIPG or progressive / recurrent / refractory H3K27-altered HGG. Each cohort will receive ACT001 at 875 mg/m2 orally BID for 28 days (1 cycle of treatment), up to a maximum dose of 1700 mg BID. If patients are experiencing clinical benefit from study therapy, they will continue to receive ACT001 in repeat 28-day cycles for up to 26 cycles (approximately 2 years) or until disease progression, whichever occurs first. Continuation of treatment beyond 26 cycles may be considered if patients are receiving clinical benefit from the study, at the discretion of the sponsor and treating physician.

Tipo di studio

Interventistico

Iscrizione (Stimato)

60

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • New South Wales
      • Randwick, New South Wales, Australia, 2031
        • Reclutamento
        • Sydney Children's Hospital
        • Contatto:
          • David Ziegler, MBBS, BSc, MD, PhD, FRACP
          • Numero di telefono: 612 9382 1730
          • Email: d.ziegler@unsw.edu.au
    • Queensland
      • South Brisbane, Queensland, Australia, 4101
        • Non ancora reclutamento
        • Queensland Children's Hospital
        • Contatto:
    • Victoria
      • Melbourne, Victoria, Australia, 3052
    • Western Australia
      • Perth, Western Australia, Australia, 6000
        • Non ancora reclutamento
        • Perth Children's Hospital
        • Contatto:
    • Ontario
      • Toronto, Ontario, Canada, M5G1X8
        • Reclutamento
        • The Hospital for Sick Children (SickKids)
        • Contatto:
    • Quebec
      • Montreal, Quebec, Canada, H4A3J1
        • Non ancora reclutamento
        • Montreal Children's Hospital
        • Contatto:
    • Baden-Wurttemberg
      • Heidelberg, Baden-Wurttemberg, Germania, 69120
        • Non ancora reclutamento
        • Hopp Children's Cancer Center at NCT Heidelberg (KiTZ)
        • Contatto:
    • Grafton
      • Auckland, Grafton, Nuova Zelanda, 1023
        • Non ancora reclutamento
        • Starship Children's Hospital
        • Contatto:
    • Colorado
      • Aurora, Colorado, Stati Uniti, 80045
    • District of Columbia
      • Washington D.C., District of Columbia, Stati Uniti, 20010
        • Reclutamento
        • Children's National Medical Center
        • Contatto:
    • Florida
      • Miami, Florida, Stati Uniti, 33155
        • Non ancora reclutamento
        • Nicklaus Children's Hospital
        • Contatto:
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30322
        • Non ancora reclutamento
        • Emory University/Children's Healthcare of Atlanta
        • Contatto:
    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48109
        • Reclutamento
        • C.S. Mott Children's Hospital
        • Contatto:
        • Contatto:
    • Missouri
      • St Louis, Missouri, Stati Uniti, 63110
        • Non ancora reclutamento
        • St. Louis Children's Hospital
        • Contatto:
        • Contatto:
    • North Carolina
      • Durham, North Carolina, Stati Uniti, 27708
        • Non ancora reclutamento
        • Duke University Medical Center
        • Contatto:
    • Ohio
      • Cincinnati, Ohio, Stati Uniti, 45229
        • Reclutamento
        • Cincinnati Children's Hospital
        • Contatto:
      • Columbus, Ohio, Stati Uniti, 43235
    • Pennsylvania
      • Philidelphia, Pennsylvania, Stati Uniti, 19104
        • Non ancora reclutamento
        • Children's Hospital of Philidelphia
        • Contatto:
    • Texas
      • Houston, Texas, Stati Uniti, 77030
        • Reclutamento
        • Texas Children's Hospital
        • Contatto:
    • Washington
      • Seattle, Washington, Stati Uniti, 98105

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 1 anno a 39 anni (Bambino, Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Patients must be ≥ 12 months and ≤ 39 years of age at the time of study enrollment.

  2. Diagnosis:

    • Cohort A: Newly Diagnosed DIPG

      • Patients with newly-diagnosed DIPG with typical MRI findings (tumors with a pontine epicenter and diffuse involvement of at least 2/3 of the pons) with or without biopsy and have completed radiation therapy (RT) within 28 to 35 calendar day prior to start of therapy.

      • Patients must have started RT <42 calendar days from radiographic diagnosis (for non-biopsied DIPG patients only) or definitive surgery, whichever is later.

        • If a biopsy was performed, the date of surgical biopsy will be considered the date of definitive diagnostic surgery; if a patient underwent two upfront surgeries [e.g., biopsy then debulking], this is the date of the second surgery)
    • Cohort B [ENROLLMENT PAUSED]: progressive/recurrent DIPG or H3K27-altered HGG OR refractory disease

      • Patients with DIPG (no biopsy required), pathologically-confirmed (at diagnosis or recurrence) H3K27-altered DIPG, or extra-pontine H3K27-alteredHGG who have progressive/recurrent or refractory disease
      • Progressive/recurrent: patients who have progressive or recurrent disease following frontline treatment must have included at least focal RT. New lesions since completion of frontline RT qualify as progressive disease.
      • Refractory disease is defined as: Presence of persistent, measurable, abnormality on conventional MRI that is further distinguished by histology or advanced imaging, OR as determined by the treating physician and discussed with the Study Chair(s) prior to enrollment.
      • Patients with H3K27-altered spinal HGG are eligible.
      • Patients with metastatic disease are eligible.
  3. Disease Status

    • Cohort A: patients may have any disease status but must have completed initial radiation therapy (RT) before enrollment.
    • Cohort B: Patients must have measurable disease assessable by MRI. Patients may have extra neuronal disease.
  4. Performance Level: Karnofsky Performance Scale score ≥ 50% for patients > 16 years of age and Lansky Performance Scale score > 50% for patients ≤ 16 years of age (applies to all patients) Note: Patients who are unable to walk because of paralysis, but who are capable of using a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.

  5. Prior anti-cancer therapy:

    • For Cohort A ONLY:
    • Surgery, radiation (focal to disease) and/or steroids (dexamethasone with goal to wean dexamethasone throughout protocol therapy) are permissible. Temozolomide administered concurrently with RT is permissible. Bevacizumab use is permitted given the last dose was administered >/= 21 days prior to enrollment. No other prior anticancer therapy for DIPG will be allowed.
    • Patients must enroll and start treatment on study between 28 and 35 calendar days post-completion of RT.
    • Patients must have started RT <42 calendar days of initial diagnosis (defined as the date of diagnostic biopsy or resection; if a patient underwent two upfront surgeries [e.g., biopsy then resection or debulking], this is the date of the second surgery).
    • Radiotherapy must have been administered at standard dose of 54 Gy for DIPG patients. Any variances in the radiotherapy dose within 10% of the standard doses outlined above will be discussed with the Study Chair to confirm eligibility prior to study enrollment.
    • For Cohort B ONLY: Patients must have fully recovered from the acute treatment related toxicities (defined as </= Grade 1 if not defined in eligibility criteria) of all prior chemotherapy, immunotherapy, radiotherapy, or any other treatment modality prior to entering on this study, with the exception of alopecia.

    Notes to the above for Cohort B: Patients with chronic Grade 2 toxicities may be eligible per discretion of the Investigator and Sponsor (e.g., Grade 2 chemotherapy-induced neuropathy). Grade 2 or 3 toxicities from prior anti-tumor therapy that are considered irreversible - defined as having been present and stable for > 6 months (such as ifosfamide-related proteinuria) may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the Investigator and Sponsor.)

    The wash out period between the prior anti-cancer chemotherapy, and enrollment must be:

    1. Myelosuppressive chemotherapy: At least 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea).

    2. Hematopoietic growth factors: At least 14 days after the last dose of a long-acting growth factor (e.g. Neulasta) or 7 days for short-acting growth factor.

    3. Biologic (anti-neoplastic agent): At least 7 days after the last dose of a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair.

    4. Immunotherapy: At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines.

    5. Monoclonal antibodies: > 21 days must have elapsed from the infusion of last dose of antibody

    6. Radiation therapy:

      • All Cohort B patients: Patients must have received their last fraction of focal irradiation to new sites of progressive disease > 14 days prior to enrollment.

        • Patients who received CSI must have received their last fraction > 3 months prior to enrollment.
      • Progressive/recurrent disease: Patients who received re-irradiation to primary disease must have received their last fraction > 3 months prior to study enrollment.

      • Refractory Disease:

        • Patients must have completed frontline RT > 6 months prior to enrollment.
        • Patients who received re-irradiation to primary disease must have received their last fraction > 3 months prior to study enrollment.
    7. Stem Cell Transplant: Patients must be ≥ 3 months since autologous stem cell transplant. Patients who received allogenic stem cell transplant or solid organ transplant are not eligible for study

  6. Organ Function Requirements (applies to all patients)

    1. Adequate bone marrow function defined as:

      • Peripheral absolute neutrophil count (ANC) > 1000/mm³
      • Platelet count > 100,000/mm³ (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
    2. Adequate renal function defined as:

      • Creatinine clearance or radioisotope GFR ≥ 70 mL/min/1.73 m² or
      • A serum creatinine based on age/gender as follows (Schwartz et al. J. Peds, 106:522, 1985): Age Maximum Serum Creatinine (mg/dL) Male Female 1 to < 2 years 0.6 0.6 2 to < 6 years 0.8 0.8 6 to < 10 years 1.0 1.0 10 to < 13 years 1.2 1.2 13 to < 16 years 1.5 1.4 ≥ 16 years 1.7 1.4
    3. Adequate liver function defined as:

      • total bilirubin must be </=1.5X institutional ULN for age
      • AST (serum glutamic-oxaloacetic transaminase [SGOT]) / ALT (serum glutamic-oxaloacetic transaminase [SGPT]) ≤ 2.5 × institutional upper limit of normal
      • Serum albumin ≥ 2 g/dL
    4. Adequate cardiac function defined as:

      • Ejection fraction of ≥ 50% by echocardiogram
      • QTc ≤ 450 msec (by Bazett formula)
    5. For Cohort B: Adequate neurologic function defined as:

      • Patients with seizure disorders may be enrolled if seizures are well- controlled. Well controlled is defined by no increase in seizure frequency in the 7 days prior to enrollment.
      • Patients with neurological deficits should have deficits that are stable for at least the 7 days prior to enrollment.
  7. Informed Consent: All patients and/or their parents or legally authorized representatives must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.

  8. Absence of other clinically significant concomitant active medical disorder, based on the investigator's judgement.

Exclusion Criteria:

A patient who meets any of the following exclusion criteria will not be eligible in the study (Applies to both cohorts except where noted below):

  1. Cohort A only: Patients with metastatic disease.

  2. Concomitant medications:

    • Corticosteroids:

      • Cohort A - Patients receiving corticosteroids are eligible regardless of dosing
      • Cohort B - Patients receiving corticosteroids who have been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are eligible
    • Anti-cancer Agents: Patients who are currently receiving other anti-cancer agents are not eligible (Refer study inclusion criteria relating to anti-cancer therapies)

      • Cohort A - Patients that have received any anti-cancer treatment other than surgery, RT, temozolomide concurrent with RT, and/or previous bevacizumab with appropriate washout period are not eligible.
    • Investigational Drugs: Patients who are currently receiving another investigational drug are not eligible.

    • Anticonvulsants should be used as clinically indicated. The use of enzyme inducing anticonvulsants is not permitted

    • LHRH agonist / antagonists are not permitted

    • High Dose Biotin (B7) supplements are not permitted

  3. Concomitant medications used with caution: selective serotonin reuptake inhibitor (SSRI) such as Lexapro, Fluoxetine (Prozac), fluvoxamine (Luvox), paroxetine (Paxil), sertraline (Zoloft), citalopram (Celexa), and escitalopram should be used with caution.

  4. Infection: Patients who currently have an uncontrolled infection (in the opinion of the PI) are not eligible.

  5. Patients who have received a prior solid organ transplantation are not eligible.

  6. Pregnant or breast-feeding women will not be entered on this study due to unknown risks of fetal and teratogenic adverse events as seen in animal/human studies. Pregnancy tests must be obtained in girls who are postmenarchal. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.

  7. Patients of childbearing or child fathering potential must agree to use adequate contraceptive methods (hormonal or barrier method of birth control; abstinence) while being treated on this study and for 3 months after completing therapy. Note: The definition of effective contraception will be based on the judgement of the principal investigator or a designated associate.

  8. Patients who are in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible.

  9. Patients who have previously received either ACT001 or parthenolide are not eligible.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Cohort A

Patients with newly-diagnosed DIPG with typical MRI findings

PO BID at 875 mg/m2 for 28 days

Sperimentale: Cohort B [ENROLLMENT PAUSED]

Patients with progressive/recurrent DIPG or H3K27-altered HGG OR refractory disease

PO BID at 875 mg/m2 for 28 days

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Overall Survival (OS) for newly diagnosed DIPG
Lasso di tempo: From date on treatment until date of death due to any cause or date of last follow-up, assessed up to 60 months

To assess the overall survival for newly-diagnosed patients with DIPG treated with RT followed by ACT001.

From date on treatment until date of death due to any cause or date of last follow-up, assessed up to 60 months
Objective Response Rate (ORR) in Progressive/Refractory/Recurrent HGG after frontline RT
Lasso di tempo: Date on treatment through 30 days following end of protocol treatment

To assess the rate of objective response rate (defined as partial response + complete response) in patients who have been treated with at least frontline focal RT and have progressive DIPG or progressive/recurrent/refractory H3K27-altered HGG who are treated with ACT001

Date on treatment through 30 days following end of protocol treatment

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Overall Survival in Progressive/Refractory/Recurrent DIPG and H3K27-altered DIPG
Lasso di tempo: From date on treatment until date of death due to any cause or date of last follow-up, assessed up to 60 months

To estimate the overall survival and duration of disease control for patients who have been treated with at least RT and have progressive DIPG or progressive/recurrent/refractory H3K27-altered HGG who are treated with ACT001

From date on treatment until date of death due to any cause or date of last follow-up, assessed up to 60 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Cattedra di studio: David S. Ziegler, MD, FRACP, Sydney Children's Hospitals Network
  • Cattedra di studio: Sara Khan, MD, PhD, FRACP, Nationwide Children's Hospital
  • Cattedra di studio: Peter de Blank, MD, MSCE, Children's Hospital Medical Center, Cincinnati

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

10 luglio 2025

Completamento primario (Stimato)

1 luglio 2028

Completamento dello studio (Stimato)

1 luglio 2035

Date di iscrizione allo studio

Primo inviato

19 febbraio 2025

Primo inviato che soddisfa i criteri di controllo qualità

19 febbraio 2025

Primo Inserito (Effettivo)

21 febbraio 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

23 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

22 ottobre 2026

Ultimo verificato

1 maggio 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • CONNECT2110

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .